基本资料 投资组合 财务数据 基金公告
创金合信全球医药生物股票发起(QDII)A(018155) |
净值：
1.7155
|
日增长率：
-1.03%
|
累计净值：1.7155 | 2026-08-10 |
|
|
||||
| 股票代码 | 股票简称 | 持股数量(股) | 持股市值(元) | 占基金净值比(%) |
| EWTX | Edgewise Therapeutics Inc | 42,071.00 | 11,642,176.02 | 4.00 |
| NAMS | NewAmsterdam Pharma Co NV | 48,197.00 | 11,124,899.06 | 3.82 |
| PTGX | Protagonist Therapeutics Inc | 13,206.00 | 11,025,426.89 | 3.78 |
| BIIB | 生化基因 | 6,734.00 | 9,909,505.61 | 3.40 |
| DNLI | Denali Therapeutics Inc | 55,296.00 | 9,686,551.34 | 3.33 |
| COGT | Cogent Biosciences Inc | 34,734.00 | 9,155,251.28 | 3.14 |
| IONS | Ionis Pharmaceuticals Inc | 13,376.00 | 7,223,525.03 | 2.48 |
| KRYS | Krystal Biotech Inc | 2,800.00 | 7,087,940.17 | 2.43 |
| CYTK | Cytokinetics Inc | 12,208.00 | 7,083,332.73 | 2.43 |
| ORIC | Oric Pharmaceuticals Inc | 96,000.00 | 7,081,156.51 | 2.43 |
| 报告期 | 股票占净比(%) | 债券占净比(%) | 现金占净比(%) | 净资产(元) |
| 2026-06-30 | 76.73 | - | 12.07 | 291,295,201.59 |
| 2026-03-31 | 79.10 | - | 20.45 | 294,545,476.27 |
| 2025-12-31 | 89.93 | - | 20.40 | 825,065,395.56 |
| 2025-09-30 | 85.79 | - | 13.08 | 39,332,950.53 |
| 2025-06-30 | 84.55 | - | 9.62 | 13,846,914.86 |
| 起始日 | 截止日 | 基金经理 | 任职天数 | 任期回报率% |
| 2026-08-05 | - | 皮劲松 | 8 | 4.90 |
| 2023-11-24 | - | 毛丁丁 | 993 | 71.55 |
| 2023-11-17 | 2026-02-10 | 皮劲松 | 816 | 67.20 |
微信公众号
证券之星APP
